Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 6.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 804,480 shares of the company’s stock after selling 55,508 shares during the period. Westwood Holdings Group Inc. owned 1.63% of Prestige Consumer Healthcare worth $62,822,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Avior Wealth Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 1,570.7% in the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company’s stock valued at $668,000 after acquiring an additional 8,042 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Prestige Consumer Healthcare by 5.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company’s stock valued at $49,667,000 after purchasing an additional 33,844 shares in the last quarter. Norges Bank acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $40,009,000. Barclays PLC increased its position in shares of Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after purchasing an additional 71,730 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in shares of Prestige Consumer Healthcare by 171.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company’s stock worth $3,665,000 after buying an additional 29,649 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Activity

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. The trade was a 8.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $89.24 on Monday. The firm’s 50 day moving average price is $83.25 and its 200 day moving average price is $81.94. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04. The firm has a market cap of $4.41 billion, a PE ratio of 20.90, a PEG ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same period in the prior year, the business posted $1.02 earnings per share. The business’s quarterly revenue was up 7.0% on a year-over-year basis. As a group, research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a research report on Thursday, May 8th. Canaccord Genuity Group upped their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Oppenheimer lifted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Finally, DA Davidson boosted their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.